Valuation: HCW Biologics Inc.

Market Cap 1.74M 1.58M 1.46M 1.32M 2.49M 162M 2.59M 17.69M 6.99M 87.61M 6.52M 6.38M 277M P/E 2026 *
-0.03x
P/E 2027 * -0.12x
Enterprise Value 1.74M 1.58M 1.46M 1.32M 2.49M 162M 2.59M 17.69M 6.99M 87.61M 6.52M 6.38M 277M EV / Sales 2026 *
0.26x
EV / Sales 2027 * -
Free-Float
92.02%
Yield 2026 *
-
Yield 2027 * -
1 day+3.73%
1 week-6.31%
Current month-26.75%
1 month-34.50%
3 months-62.17%
6 months-89.98%
Current year-86.16%
1 week 0.74
Extreme 0.7428
0.89
1 month 0.74
Extreme 0.7428
1.34
Current year 0.74
Extreme 0.7428
23.94
1 year 0.74
Extreme 0.7428
23.94
3 years 0.74
Extreme 0.7428
604.8
5 years 0.74
Extreme 0.7428
796.8
10 years 0.74
Extreme 0.7428
1,866
Manager TitleAgeSince
Chief Executive Officer 72 2018-04-01
Director of Finance/CFO 70 2019-09-30
Chief Tech/Sci/R&D Officer 68 2019-04-30
Director TitleAgeSince
Director/Board Member 72 2018-04-01
Chairman 76 2021-05-31
Director/Board Member 61 2021-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/29/26 Buy

Chairman

7,736 0.4845%
7/29/26 Buy

Executive/Senior Manager

7,736 0.4845%
7/29/26 Buy

Founder

23,210 1.4535%
Change 5-day change 1-year change 3-year change Capi.($)
+3.73%-6.31%-94.43%-99.69% 1.74M
-1.34%-4.12%+53.70%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.68% 58.86B
+0.54%+0.45%+25.96%+86.62% 55.22B
-2.22%-3.77%+11.05%+115.11% 47.21B
+0.06%-5.90%+18.89%+25.83% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.34%-11.24%+127.25%+638.13% 35.19B
-0.17%-1.83%+82.46%+57.48% 32.66B
-1.24%-0.41%-40.35%+388.46% 26.73B
Average -0.38%-4.29%+20.82%+141.27% 40B
Weighted average by Cap. -0.75%-2.92%+33.60%+143.19%

Financials

2026 *2027 *
Net sales 6.68M 6.09M 5.63M 5.08M 9.57M 624M 9.95M 68.02M 26.89M 337M 25.06M 24.53M 1.06B -
Net income -9.62M -8.78M -8.11M -7.32M -13.79M -899M -14.33M -97.99M -38.74M -485M -36.1M -35.34M -1.53B -14.31M -13.05M -12.07M -10.89M -20.51M -1.34B -21.32M -146M -57.62M -722M -53.7M -52.57M -2.28B
Net Debt - -
Projected Income Statement - Annual - HCW Biologics Inc.
Logo HCW Biologics Inc.
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Employees
35
Date Price Change Volume
26-11-18 US$0.8057 +3.73% 5,814
26-11-17 US$0.7767 -2.91% 15,291
26-11-16 US$0.8000 +3.48% 88,134
26-11-13 US$0.7731 -3.43% 22,461
26-11-12 US$0.8006 -6.91% 36,381
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.7767USD
Average target price
48.00USD
Spread / Average Target
+6,079.99%
  1. Stock Market
  2. Stocks
  3. HCWB Stock